Neurodegenerative Disorders Drug Development Pipeline Review 2017: Small Molecule Drugs Dominate the Pipeline - Research and Markets

News provided by

Apr 27, 2017, 07:45 ET

DUBLIN, April 27, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Neurodegenerative Disorders Drug Development Pipeline Review, 2017" report to their offering.

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

Companies Mentioned

AB Science SA
AC Immune SA
AFFiRiS AG
ALSP Inc.
AbbVie Inc
Accera Inc.
Acelot Inc.
Actinogen Limited
Acumen Pharmaceuticals Inc.
Addex Therapeutics Ltd
Affibody AB
Alector LLC
Alkermes Plc
Allergan Plc
Allinky Biopharma
AlzProtect SAS
Alzhyme Pty Ltd
Alzinova AB
Amarantus Bioscience Holdings Inc.
Amgen Inc.
(100+ Others)

Key Topics Covered:

1. Research Report Guidance

2. Executive Summary

3. Introduction

4. Neurodegenerative Disorders Report Coverage

5. Therapeutics Development

6. Therapeutics under Development by Companies

7. Therapeutics under Investigation by Universities/Institutes

8. Pipeline Products Glance

9. Products under Development by Companies

10. Products under Investigation by Universities/Institutes

11. Companies Involved in Therapeutics Development

12. Therapeutics Assessment

13. Dormant Projects

14. Discontinued Products

15. Product Development Milestones

16. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/jxqkhq/neurodegenerative

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets